Canopy Growth Corporation is launching a study that looks at the effectiveness of cannabidiol (CBD) in treating anxiety in some animals.
The research will be conducted by the company’s subsidiary Canopy Health Innovations, which focuses on developing cannabis-based healthcare products for companion animals.
“Our passion to create safe and effective products for animals is driven by the love we share for our pets,” said Marc Wayne, Managing Director of Canopy Health Innovations.
“The use of natural-occurring cannabinoids as a therapy for companion animals is a logical new forefront of medical discovery and the research we are working on at CAH is world leading,” he added. “These trial approvals mark a significant milestone on the journey of making cannabis-based drugs accepted and recommended by veterinarians.”
The approval comes in the form of a “No Objection Letter” for the use of a proprietary CBD enriched oil formulation, previously administered in pre-clinical dosing and safety studies, as a potential therapy for anxiety.
The CBD formulation will be produced by Canopy Growth in its GMP-certified production facility in Smiths Falls, Ontario.
Canopy Animal Health describes itself as “the global leader in cannabinoid science for pets,” and says it “continues to build a strong portfolio of safety and dosing data for certain animals which it plans to share with the veterinary community and pet owners, through publications and scientific conferences.”
Canopy Health continues to focus on the “robust research and development of innovative cannabis-related products.””
Recently, it was announced that Canopy Growth had acquired the remaining unowned interest in Canopy Health, a move that is said will “further accelerate CHI’s efforts to research effective cannabis formulations and dose delivery systems for human and animals.”